Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib plus dexamethasone versus physician's choice in relapsed or refractory systemic light chain amyloidosis
2011-005468-10Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ixazomib in light-chain amyloidosis (2 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Overall hematologic response rate. Started Aug 2012; status: completed.
02
Drugs
ixazomib
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2011-005468-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005468-10.